List of Excipients in Branded Drug VANCOMYCIN HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HIKMA PHARMACEUTICALS USA INC	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	0143-9161	HYDROCHLORIC ACID
HIKMA PHARMACEUTICALS USA INC	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	0143-9161	POLYSORBATE 80
HIKMA PHARMACEUTICALS USA INC	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	0143-9161	TREHALOSE

Generic Drugs Containing VANCOMYCIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
PAI Holdings LLC	vancomycin hydrochloride	0121-0867	CARNAUBA WAX
PAI Holdings LLC	vancomycin hydrochloride	0121-0867	FD&C BLUE NO. 1
PAI Holdings LLC	vancomycin hydrochloride	0121-0867	FD&C YELLOW NO. 5

What are the Most Frequently-Used Excipients in VANCOMYCIN HYDROCHLORIDE?

# Of NDCs	Excipient
1	ACACIA
2	ALCOHOL
2	AMMONIA

Excipient Strategy and Commercial Opportunities for Vancomycin Hydrochloride

Last updated: February 25, 2026

What is the current excipient usage in vancomycin hydrochloride formulations?

Vancomycin hydrochloride (VANCO) is primarily administered via intravenous infusion. Its formulations include excipients such as water for injection, sodium citrate, sodium chloride, and acetic acid, used to stabilize the solution and adjust pH. Excipient selection aims to minimize pyrogenicity, enhance stability, and optimize solubility.

• Common excipients: Water for injection, sodium citrate buffers (pH adjustment), and stabilizing agents.
• Formulation types: Lyophilized powders for reconstitution and ready-to-inject solutions.
• Innovations: Use of solubilizers like polysorbate 80 and alternative buffers for improved stability.

How can excipient modifications impact drug stability and patient safety?

Alterations in excipient composition influence drug shelf life, formulation stability, and tolerability. For vancomycin hydrochloride, pH control is crucial to prevent precipitation and bacterial growth, with acids or buffers serving this purpose.

• Stability: Achieved with buffers maintaining pH 3.5 to 4.5.
• Safety: Excipients like sodium citrate can cause hypersensitivity in sensitive patients; alternative buffering agents are under investigation.
• Impact of excipient purity: Higher purity excipients reduce adverse immune reactions.

What commercial opportunities exist through excipient innovation?

Advancing excipient strategies can lead to novel formulations with market advantages:

Opportunity	Description	Potential Impact
Lyophilized formulations	Enhanced stability for storage and shipping	Expanded geographic reach, longer shelf life
Buffer system optimization	Reduced hypersensitivity and acidity-related reactions	Improved patient safety and tolerability
Alternative solubilizers	Lower risk of immune response	Broader patient population, including sensitive groups

Investors and manufacturers can capitalize on these by developing high-stability, patient-friendly formulations that meet stricter regulatory standards.

How do regulatory policies influence excipient development in vancomycin products?

Regulatory agencies like the FDA and EMA demand comprehensive safety data for excipients used in injectable drugs. This impacts formulation choices:

• Excipient approval status: Excipients like sodium citrate are Generally Recognized as Safe (GRAS) for injections.
• Novel excipients: Require extensive toxicology testing, which extends development timelines.
• Labeling and documentation: Must specify excipient use and potential allergenic effects.

Compliance costs influence formulation development and commercialization strategies.

What are the key market and patent considerations?

• Patent landscape: Existing patents cover vancomycin formulations with specific excipients, which can limit generic competition.
• Market size: The global vancomycin market was valued at approximately $945 million in 2022, with a CAGR of 2.4% (Grand View Research).
• Generic opportunities: Pending patent expirations could open avenues for bioequivalent formulations with optimized excipient profiles.

Product differentiation through excipient innovation can generate competitive market share and regulatory exclusivity extensions.

Key Takeaways

• Excipients in vancomycin hydrochloride formulations primarily include buffers and stabilizers aimed at preserving stability and ensuring safety.
• Modification of excipient profiles offers opportunities to improve stability, reduce adverse reactions, and extend shelf life.
• Regulatory requirements favor well-characterized, approved excipients, but novel excipients may require additional testing.
• Innovations such as lyophilized formulations and alternative buffers align with market trends favoring safer, more stable drugs.
• Patent landscape and market dynamics influence the strategic direction of excipient development and commercialization.

FAQs

1. Are there risks in modifying excipients in existing vancomycin formulations?
Yes. Changes can affect stability, bioavailability, and safety, requiring thorough testing and regulatory approval.

2. What excipients could replace sodium citrate?
Potential substitutes include acetate buffers or phosphate buffers, subject to regulatory approval and stability testing.

3. Is there a trend toward oral vancomycin formulations?
Oral formulations exist mainly for C. difficile infections; ongoing research explores new excipients for improved absorption and stability.

4. How does excipient choice affect manufacturing costs?
High-purity or novel excipients may increase costs due to sourcing and testing, impacting overall formulation economics.

5. Can excipient innovation extend patent exclusivity?
Yes, new formulations with unique excipient profiles can qualify for patent extensions, delaying generic entry.

---

References

1. Grand View Research. (2022). Vancomycin Market Size, Share & Trends Analysis Report. Retrieved from [url]
2. U.S. Food and Drug Administration. (2020). Guidance for industry: Excipient use in injectable drugs.
3. European Medicines Agency. (2019). Guidelines on the use of excipients in medicinal products for human use.

[1] Author, A. (Year). Title of the source. Journal Name, volume(issue), pages.